Introductory Chapter: Biopharmaceuticals by Chen, Yuan-Chuan & Yeh, Ming-Kung
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Introductory Chapter: Biopharmaceuticals
Yuan-Chuan Chen and Ming-Kung Yeh
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.79194
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
   
1. Introduction
A biopharmaceutical (biological or biologic), which consists of sugars, proteins, nucleic acids, 
living cells, or tissues, is a medicinal product manufactured in extracted or semi-synthesized 
from biological sources like humans, animals, or microorganisms. Different from traditional 
drugs synthesized from chemical processes, the majority of biopharmaceutical products are 
derived from biological processes including the extraction from living systems or the produc-
tion by recombinant DNA technologies (Table 1). Transgenic organisms, especially plants, 
animals, or microorganisms that have been genetically modified, are potentially used to pro-
duce biopharmaceuticals.
The recombinant human insulin (trade name “Humulin”) was the first biopharmaceutical 
approved for human therapeutic uses and marketing in 1982. Currently, biopharmaceuticals 
have been extensively used as therapeutic agents such as vaccines, whole blood (or blood 
components), immunosera, antigens, hormones, cytokines, enzymes, allergenics, cell thera-
pies, gene therapies, tissues, monoclonal antibodies, and products derived from recombinant 
DNA, etc. For example, vaccines are used to prevent infectious diseases and some cancers; 
cell- and gene-based biopharmaceuticals are applied to treat a variety of diseases for which 
no other drugs or medical devices are available.
The European Medicines Agency (EMA) uses the specific term “advanced therapy medici-
nal products (ATMPs)” to refer to human medicines that are based on cells, genes, or tissue 
engineering. Cell therapy products (CTPs) are biomedicines containing cells/tissues that have 
been manipulated to change their biological characteristics, and these cells/tissues can be 
used to treat, prevent, or diagnose diseases [1]. Gene therapy products (GTPs) are therapeutic 
agents to make genetic improvement through the repair, deletion, insertion, or substitution of 
mutated genes or site-specific modifications for target therapies [2]. Tissue engineering is the 
application of a combination of cell, engineering, and material methods, and suitable factors 
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are added to improve, repair, or replace only part of or whole biological tissues such as bones, 
cartilages, blood vessels, organs, skins, muscles, etc. It also involves the use of a tissue scaffold 
for the formation of new viable tissues for medical purposes [3–5].
A biosimilar, also known as “follow-on biologic,” is a biologic medical product that is almost 
identical to a copy of an original product manufactured by different pharmaceutical com-
panies. It is highly similar to a licensed reference product in spite of minor differences in 
clinically inactive components. There are no clinically significant differences between the 
biosimilars and the reference products in terms of the safety, purity, and potency. A generic 
drug is the same as a brand name drug in dosage, safety, strength, administration, quality, 
performance, and intended uses. It is required to take a lot of rigorous tests to ensure that the 
generic drug can substitute for the brand name drug. A generic drug must contain identical 
active pharmaceutical ingredients (APIs) with the same amount as the brand name product 
and be proved to be bioequivalent to the brand name drug. The substitutability or therapeutic 
equivalence of generic drugs has to be evaluated scientifically. If a generic drug is evalu-
ated as therapeutically equivalent as the brand name product, it has equal effects and show 
no differences compared with the brand name product. Biosimilars, like generic drugs, can 
be manufactured when the original “innovator” product’s patent expires, and are officially 
approved versions of the original products [6]. However, there are many differences between 
a generic drug and a biosimilar (Table 2). Biosimilars have the same clinical effect as generic 
drugs but are only similar to the original “innovator” drugs as they are confirmed by valida-
tion methods. Biosimilars will not be the same as the reference products, unlike generic drugs 
in which the APIs are identical to the references [7]. Despite this heterogeneity, all generic 
drugs and biosimilars have to maintain consistent quality and effective performance through-
out their life cycles [8].
Source item Extracted from living systems Produced by recombinant DNA
Characteristic 1. Some conventional biopharmaceuticals are 
extracted from animals or humans particularly.
2. Some biopharmaceuticals were extracted from 
animals, but they are currently produced by 
biotechnologies. For example, the therapeutic 
insulin previously extracted from porcine pan-
creatic islets is now produced by recombinant 
DNA technologies in the yeast (Saccharomyces 
cerevisiae) or E. coli.
Biopharmaceuticals produced by 
recombinant DNA technologies are usually 
one of the following three types:
1. Substances that are almost identical to the 
body’s own key signaling proteins.
2. Monoclonal antibodies that are similar to 
the antibodies produced by the human 
immune system against microbes.
3. Receptor constructs (fusion proteins) that 
are usually based on a naturally occurring 
receptor linked to the immunoglobulin 
frame.
Example Whole blood and blood components, organs and 
tissue transplants, stem cells, antibodies for passive 
immunization, fecal microbiota, human breast milk, 
human reproductive cells
Blood factors, tissue plasminogen activators, 
hormones, hematopoietic growth factors, 
interferons, interleukin-based products, 
vaccines, monoclonal antibodies, tumor 
necrosis factors, therapeutic enzymes
Table 1. Major sources of biopharmaceuticals.
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2. Application
Biopharmaceuticals have multiple clinical applications and various advantages for disease 
therapy, prevention, and diagnosis.
2.1. Therapy
The therapeutic types of biopharmaceuticals mainly include recombinant protein therapy, 
antibody therapy, cell therapy, and gene therapy. Biopharmaceuticals are able to cure or 
treat diseases safely and effectively by demonstrating biological activity, and perform spe-
cific functions by acting on the disease pathophysiology. Compared with chemical drugs, 
biopharmaceuticals are more complex in production, have multiple routes of administration 
and different pharmacokinetics. Their advantages are high selectivity and low nonspecific 
toxicity; disadvantages include high costs and the induction of antidrug antibodies leading to 
decreased efficacy or deficiency in biosafety. Treatment can be optimized through the devel-
opment of dosing schedules and multiple administrative routes. Additionally, the cost can be 
reduced by using biosimilars.
2.2. Prevention
A vaccine is the most important biopharmaceutical used for infectious disease prevention. 
It usually contains a biological agent that resembles a pathogen and is usually made from 
Drug property Generic drug Biosimilar
Molecular size Small (~150 Da) Large (~150,000 Da)
Structure Simple and well-defined Complex with probable structural 
variations
Characterization Easy Difficult
Stability More stable for storage and handling Less stable, very sensitive to its 
surroundings
Production Predictable chemical processes are used 
to manufacture an identical copy
Specialized biological processes are used 
to manufacture a similar copy
Identical to reference products Yes
At least, active pharmaceutical 
ingredients are identical
No
Minor differences in clinically inactive 
components are acceptable
Adverse immune responses Lower potential Higher potential
Frequency of quality tests in 
manufacturing
≤50 ≥250
Clinical trials requirement for 
approval
Small clinical trials in healthy 
volunteers
Large clinical trials in patients
Discovery cost Low or even no Relatively high
Table 2. Comparison of a generic drug and a biosimilar.
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inactivated microbes, live attenuated microbes, toxoids (toxins), and or part of surface anti-
gens (subunits). Through vaccination, the burst of many infectious diseases has enormously 
been decreased such as measles, tetanus, and polio; some are even eradicated such as small-
pox. However, the burden of noninfectious diseases such as cancers, cardiovascular diseases, 
metabolic diseases, and neurodegenerative diseases is significantly increasing. Currently, 
some vaccines are successfully applied to prevent cancers; for example, the human papilloma 
virus (HPV) vaccine has been approved for the prevention of cervical cancers.
2.3. Diagnosis
In addition to clinic significance in therapy and prevention, some biopharmaceuticals can 
be used to diagnose diseases; for example, monoclonal antibodies have been successfully 
applied in the diagnosis of some cancers and infectious diseases, and more are being devel-
oped [9–11]. Once monoclonal antibodies specified for a given substance are produced, they 
can be used to detect the presence of this substance. They are also very useful in immunohis-
tochemistry that detects antigens in fixed tissue sections and immunofluorescence tests that 
detect the substance in frozen tissue sections or in live cells.
3. Perspective and challenge
For recent studies, innovative biopharmaceuticals are developing rapidly and have opened a 
new era for human therapy. Many researchers involve in the development of biopharmaceuti-
cals and achieve exciting results. Biopharmaceuticals are promising for scientific perspectives 
and regulatory perspectives. Nonetheless, there are still some challenges including scientific 
issues and regulatory issues we need to overcome.
3.1. Scientific issue
Along with the advance of biotechnologies, more novel biopharmaceuticals are marketed and 
used for clinical application in the world. Biopharmaceuticals have been extensively applied 
for disease control, prevention, and diagnosis even though some scientific challenges are still 
unsolved. Take vaccines and gene therapies as examples to discuss as follows:
3.1.1. Vaccine
Vaccination, the administration of an antigenic material (vaccine), is considered to be the most 
effective strategies for disease control. Appropriate formulation and delivery of vaccines can 
maximize the potential advances for disease prevention. The main advantages of vaccination 
include the prevention in advance and the immunity for long term; the limitations are complex 
vaccination schedules, strict requirements for storage, and restricted routes of administration 
[12]. Nanotechnology is an approach to prepare a nanovaccine with the consumption and 
side effects significantly decreased. Through the application of nanoparticles, it is possible 
for vaccines to be controlled release at specific location, stable at room temperature, and have 
replaceable routes for administration. Vaccines based on nanotechnologies may overcome 
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their limitations and result in the development of painless, safe, effective, and economic 
products. The major challenges are the toxicity of nanoparticles and the immune responses 
induced by nanoparticles, though some biodegradable and biocompatible nanoparticles have 
been developed [12].
Biotechnologies using recombinant DNA technologies, genetic engineering, and tissue culture 
encompass a wide range of procedures to modify living organisms for human uses. New vac-
cines employing biotechnologies improve the product quality and expand the clinical appli-
cations [13]. For example, traditional vaccines are only used to prevent infectious diseases, 
but vaccines based on biotechnologies are being developed to prevent many noninfectious 
diseases such as cancers, type I diabetes mellitus (T1DM), Alzheimer disease, drug addiction, 
etc. [13]. In addition, therapeutic vaccines are potentially developing for both infectious and 
noninfectious diseases using the biotechnologies such as reverse vaccinology, recombinant 
subunit vaccination, recombinant protein vaccination, DNA vaccination, and RNA vaccina-
tion. The major challenge is complex vaccination schedules. The vaccines based on biotech-
nologies are usually only parts of microorganisms (DNA, RNA, or protein); therefore, it is 
required to have multiple doses to induce additional “booster” shots for full immunity [13].
3.1.2. Gene therapy
Although many CTPs have been approved for marketing in many countries and extensively 
used for disease treatment [1], current gene therapies predominantly exist in basic research 
laboratories and their clinical applications are still on trials. Despite of this, some GTPs have 
been approved by the EMA such as Glybera (alipogene tiparvovec) in 2012, and by the United 
States Food and Drug Administration (US FDA) such as Kymriah (tisagenlecleucel) and 
Yescarta (axicabtagene ciloleucel) in 2017, respectively. Recently, gene therapies have become 
possible through the advances of genetic engineering technology that enabled the manipula-
tion of genome and the development of delivery tools such as lipoids [2, 14], viruses [2, 14], 
nanoparticles [2, 14], bacteria [15], gene guns [16], electroporation [17], or nanostraws [18]. 
Therapeutic components must be transported to targeted cells to exert a therapeutic effect. 
Therefore, the delivery tool is essential for drug delivery to target cells and it is very crucial to 
select a suitable delivery tool with specificity, efficiency, safety, and economics. However, it is 
challenging for the option of delivery tools due to the following issues.
1. Specificity: Some delivery tools are not very specific and may deliver nucleic acids to non-
target cells. It is important to reduce the risk of nonspecific delivery, but the evaluation of 
their benefits and risks is complex.
2. Efficiency: Not all delivery tools are efficient enough; some of them are low in efficiency 
and multiple rounds of transfections are needed. Additionally, it is hard to improve and 
evaluate their efficiency especially in animals and clinics.
3. Biosafety: Some delivery tools are toxic, biohazardous, or even destructive to normal cells 
or recipient hosts. Some delivery tools such as lipoids, viruses, bacteria, and nanoparticles 
may induce vector-associated immune responses in hosts, and to overcome immune barri-
ers is essential [14]. Consequently, it is required to verify their safety in preliminary tests.
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4. Economics: The research and development (R&D) of delivery tools is perhaps difficult, 
risky, costly, and time-consuming. Consequently, researchers, funders, and manufactur-
ers must have enough incentives to develop delivery tools. In fact, most biotechnology 
companies have little incentive to discover novel delivery tools because of limited revenue 
and highly developmental risks.
In several recent studies, encouraging progresses have been made to possibly overcome the 
challenges of delivering GTPs in vivo [19–22] (Table 3).
3.2. Regulatory issue
Biopharmaceuticals are more complex than small molecular-weight drugs due to their biolog-
ical source, large molecular size, structural complexity, and environmental sensitivity. Thus, 
it is essential to consider specific and special regulatory issues for the research, production, 
clinical trials, applications, and marketing of biopharmaceuticals, though many professional 
regulations and developmental frameworks have already been established. Take cell thera-
pies and gene therapies, and biosimilars as examples to discuss as follows:
3.2.1. Cell therapy and gene therapy
CTPs and GTPs have the trend to be commodified because many manufacturers are aiming 
at pursuing commercial interests. Commercial promotion of unsupported therapeutic uses of 
CTPs and GTPs has become global challenges that have proven resistant to regulatory efforts. 
Some unapproved or unproved CTPs and GTPs are tried on patients only according to their 
indefinite perspectives. Some CTPs and GTPs which clinical trials or data are still incom-
plete are prematurely released on the market only due to significant interests. A coordinated 
approach at the national and international levels focused on engagement, harmonization, and 
enforcement must be implemented to reduce the risks related to direct consumer marketing of 
unapproved or unproven CTPs and GTPs [23]. However, in some cases, some CTPs or GTPs 
have not yet completed their efficacy validation, but they have enough data to verify their 
Challenge Strategy
Specificity Discovery of a specific virus such as adeno-associated viruses (AAVs)
Efficiency Application of a combination system such as AAVs-CRISPRs
Biosafety Combination with several factors such as smaller Cas9 orthologues, tissue-specific minimal 
promoters, AAV serotypes, and different routes of administration;
Development of novel and safe delivery tools such as lipid nanoparticles (LNPs), AAVs, and 
baculoviruses
Economics International collaboration among manufacturers and harmonization for product review and 
approval in different countries can raise the profits and reduce the expenses
Abbreviation: clustered regularly interspaced short palindromic repeats (CRISPRs)/Cas9 nuclease system.
Table 3. Possible strategies for overcoming the challenges for drug delivery (cited from Table 3. Potential Application of 
the CRISPR/Cas9 System against Herpesvirus Infections. Viruses. 2018 May 29;10(6). pii: E291).
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safety and estimate their efficacy. For the therapy of patents, who are in serious conditions or 
unmet medical needs, specific CTPs or GTPs can be accessible to these patients with adaptive 
licensing [1]. The regulator should establish a conditional approval system in the regulation 
with deadline, a fast-track review, and communication mechanism to have patients in urgent 
needs take specific CTPs or GTPs as soon as possible.
3.2.2. Biosimilar
As products of living organisms, biopharmaceuticals are more complicated than small molec-
ular-weight chemical drugs because of their sensitivity to manufacturing processes and post-
translational changes [24]. Most information on the manufacturing process is not fully open to 
the public, because it may be proprietary or a patent. This information gap stands for a critical 
challenge for biosimilar developers and plays a crucial role in explaining the differences in regu-
latory pathways. It is required to demonstrate biosimilarity and assure that the change in manu-
facturing process represents no effects on safety and efficacy. The extent of the change is usually 
a key indicator to the analysis required to evaluate the quality. Biosimilarity exercises have been 
addressed differently by regulators to realize that biosimilar developers begin with fundamental 
differences including culture media, purification processes, and formulations [24]. Therefore, 
it is required to ensure that the changes do not influence the efficacy and safety of biosimilars.
Biosimilars are defined and present their financial and clinical implications in current publica-
tions, regulations, and the US FDA guidance documents [25]. Some biopharmaceuticals may be 
replaced with cheaper biosimilars when they lose the patent protection. However, unlike generic 
drugs, biosimilars are different from the reference products in structure and function. The US 
Biologics Price Competition and Innovation (BPCI) Act of 2009 created an abbreviated licensure 
pathway to allow for the development and approval of biosimilars and interchangeable refer-
ence products that are licensed [25, 26]. The US FDA can approve biosimilars via the abbrevi-
ated licensure pathway in accordance with the BPCI Act. Biosimilars approved in Europe are 
only composed of simple and small molecules. Complex and large-molecule biosimilars will be 
subjected to a more rigorous and prolonged approval processes [25]. The financial success of 
biopharmaceutical therapies and their patent expiration eventually result in the development 
of biosimilars. The pharmaceutical company has to develop complex biosimilars that mimic 
the original “innovator” drugs and explore analytical methods to demonstrate similarity to 
regulatory authorities [25]. A comment outlines the efforts of an integrated health system to 
ensure biosimilar accessibility and discusses the current challenges and future implications 
[27]. Biosimilars still confront regulatory challenges on potential implications for pricing, site of 
care, and pharmacy dispensing practices [27]. Generally, we believe that biosimilars are helpful 
to the health-care system, but their expected benefits may not be understood in the near future.
4. Conclusion
Biopharmaceuticals are very promising for disease control and prevention due to their char-
acteristics and multiple advantages over traditional drugs. Many novel biopharmaceuticals 
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are being developed and may be applied for clinical application in the near future, though 
some scientific and regulatory issues are still unsolved. We expect research works including 
the discovery, production, applications, prospects, and challenges of biopharmaceuticals to 
gain the fruitful outcome and have a great impact over the humans. All prospects will come 
true and challenges will be overcome eventually if we constantly endeavor.
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